LakeShore Biopharma Co., Ltd (LSBCF)

Revenue by Segment

Financials in millions CNY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Development, Production, Marketing and Sale of Biopharmaceutical Products	614.96M	573.42M	687.20M	502.95M	257.02M
Development, Production, Marketing and Sale of Biopharmaceutical Products Growth	7.24%	-16.56%	36.63%	95.69%	-
Total	614.96M	573.42M	687.20M	502.95M	257.02M
Total Growth	7.24%	-16.56%	36.63%	95.69%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error